MedTrace Logo

Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)

NCT01159847 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-07-31

No results posted yet for this study

Summary

The aim of this study is to investigate the protective effects of sitagliptin on β cell function in patients with adult-onset latent autoimmune diabetes (LADA) and its mechanisms.

Conditions

Interventions

DRUG

sitagliptin

sitagliptin tablet,100 mg p.o. qd,2 year

DRUG

Insulin

Sponsors & Collaborators

  • Chinese Medical Association

    collaborator NETWORK

  • Eli Lilly and Company

    collaborator INDUSTRY

  • European Foundation for the Study of Diabetes

    lead OTHER

Principal Investigators

  • Zhiguang Zhou, M.D., Ph.D. · Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-07-31
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01159847 on ClinicalTrials.gov